-
Je něco špatně v tomto záznamu ?
Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy
T. Buchler, A. Poprach
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články, přehledy
Grantová podpora
NU21-03-00539
Ministerstvo Zdravotnictví Ceské Republiky
NLK
ProQuest Central
od 2006-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2006-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 2006-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2006-01-01 do Před 1 rokem
Family Health Database (ProQuest)
od 2006-01-01 do Před 1 rokem
- MeSH
- imunoterapie MeSH
- inhibitory proteinkinas farmakologie terapeutické užití MeSH
- inhibitory tyrosinkinasy MeSH
- karcinom z renálních buněk * patologie MeSH
- lidé MeSH
- nádory ledvin * farmakoterapie patologie MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Several regimens combining immunotherapy and tyrosine kinase inhibitors (TKIs) have recently been validated for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). While immunotherapy is typically discontinued after 2 years in patients who neither progress nor experience limiting toxicity, according to the protocols of most recent phase III clinical trials, TKIs are to be continued until disease progression or the emergence of limiting toxicity. However, the prolonged use of TKIs is associated with significant toxicity and financial costs. This has sparked considerable debate about whether TKIs can be safely discontinued, particularly in mRCC patients who have achieved a verified complete response. This concise review examines the available evidence on TKI discontinuation in the context of mRCC management.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006884
- 003
- CZ-PrNML
- 005
- 20240423155543.0
- 007
- ta
- 008
- 240412s2024 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11523-023-01031-y $2 doi
- 035 __
- $a (PubMed)38308662
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Buchler, Tomas $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06, Prague, Czech Republic. tomas.buchler@fnmotol.cz $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic. tomas.buchler@fnmotol.cz $1 https://orcid.org/000000016667994X $7 xx0096851
- 245 10
- $a Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy / $c T. Buchler, A. Poprach
- 520 9_
- $a Several regimens combining immunotherapy and tyrosine kinase inhibitors (TKIs) have recently been validated for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). While immunotherapy is typically discontinued after 2 years in patients who neither progress nor experience limiting toxicity, according to the protocols of most recent phase III clinical trials, TKIs are to be continued until disease progression or the emergence of limiting toxicity. However, the prolonged use of TKIs is associated with significant toxicity and financial costs. This has sparked considerable debate about whether TKIs can be safely discontinued, particularly in mRCC patients who have achieved a verified complete response. This concise review examines the available evidence on TKI discontinuation in the context of mRCC management.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z renálních buněk $x patologie $7 D002292
- 650 _2
- $a inhibitory tyrosinkinasy $7 D000092004
- 650 12
- $a nádory ledvin $x farmakoterapie $x patologie $7 D007680
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $x terapeutické užití $7 D047428
- 650 _2
- $a imunoterapie $7 D007167
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Poprach, Alexandr $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06, Prague, Czech Republic
- 773 0_
- $w MED00189571 $t Targeted oncology $x 1776-260X $g Roč. 19, č. 2 (2024), s. 175-180
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38308662 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155540 $b ABA008
- 999 __
- $a ok $b bmc $g 2081076 $s 1216651
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 19 $c 2 $d 175-180 $e 20240203 $i 1776-260X $m Targeted oncology $n Target Oncol $x MED00189571
- GRA __
- $a NU21-03-00539 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20240412
